ADHERENCE TO PROTEASE INHIBITORS

描述（改编自摘要）：蛋白酶抑制剂需要 艾滋病病毒感染者（PWHIV）严格遵守严格的 治疗方案只是少服几剂或者改变间隔 剂量之间可能导致病毒载量增加，CD 4 T细胞减少， 计数以及耐药突变株的开发。研究人员 正在受到挑战，以证明干预措施的有效性， 提高依从性;然而，没有对PWHIV患者进行干预研究， 采用包括蛋白酶抑制剂在内的联合疗法， 公开.因此，本研究的主要目的是比较 习惯训练和问题解决干预的效果 注意对包括蛋白酶抑制剂在内的联合治疗的依从性。 这个12次电话干预和12周的维护计划是 基于社会学习理论和自我效能理论。样品 在200名正在接受联合治疗的PWHIV患者中， 抑制剂，并且没有认知功能障碍、酒精和/或 注射吸毒和/或慢性情绪障碍/人格 疾病将被随机分配到两个方案组中的一个。的 干预组将接受为期12周电话干预 然后是为期3个月的每周电话维护计划。数据 将在基线、治疗后、维持治疗后和6- 维护后数月。药物电子监测系统（MEMS） TrackCaps、每日日记和药丸计数将用于评估 坚持。将使用医学结局测量疗效调节因子 研究-HIV（情绪和身体功能）、症状困扰量表和 贝克抑郁量表II将使用以下指标评估临床缓解 病毒载量和CD 4 T细胞计数。重复测量模型， 将使用比较来检验主要目的的假设 （p<.05，双尾）。将使用纵向数据分析技术。 坚持治疗的PWHIV患者将活得更长，需要的时间更少 住院治疗，不熟练的护理，更少的家庭护理，因此， 降低他们的医疗费用。

DESCRIPTION (adapted from the Abstract): Protease inhibitors require persons with HIV (PWHIV's) infection to adhere strictly to the rigorous therapeutic regimen. Missing just a few doses or changing the intervals between doses may lead to increase in viral load, decreases in CD4 T-cell counts, and the development of drug-resistant mutant strains. Researchers are being challenged to demonstrate the efficacy of interventions to enhance adherence; however, no intervention studies with PWHIV's who are taking combination therapy including protease inhibitors have been published. Therefore, the primary aim of this study is to compare the effect of the habit-training and problem-solving intervention with usual care on adherence to combination therapy including a protease inhibitor. This 12-session telephone intervention and 12-week maintenance program is based on social learning and theory and self-efficacy theory. The sample of 200 PWHIV's who are taking combination therapy including protease inhibitor, and who are without cognitive dysfunction, alcohol and/or injection drug abuse, and/or chronic emotional disorders/personality disorders will be randomly assigned to one of two protocol arms. The intervention arm will receive a telephone-delivered 12-week intervention followed by a 3-month maintenance program of weekly telephone calls. Data will be collected at baseline, post-treatment, post-maintenance, and 6- months post-maintenance. Medication Electronic Monitoring System (MEMS) TrackCaps, daily diaries, and pill counts will be used to assess adherence. Efficacy moderators will be measured using the Medical Outcomes Study-HIV (mood and physical function), the Symptom Distress Scale, and the Beck Depression Inventory-II. Clinical response will be assessed using viral load and CD4 T-cell count. A repeated-measures model with planned comparisons will be used to test the hypotheses for the primary aim (p<.05, two-tailed). Longitudinal data analytic techniques will be used. PWHIV's who adhere to therapy will live longer and require fewer hospitalizations, less skilled nursing care, and less home care, thus reducing the costs of their health care.